11 Days
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
11 Daysالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
11 DaysReady to play
Ready to play
Initial human trials have revealed that an experimental injection called "CBL-514" can reduce accumulated visceral fat in the abdomen, which impacts metabolism and insulin resistance, and plays a role in the development of heart disease and type 2 diabetes. The results showed that the average fat volume decreased by about 12% after four weeks of treatment, though the studies are still in their early stages and do not guarantee the effectiveness or safety of its long-term use. Further experiments are needed to more broadly assess its safety and efficacy.
Notice: This Is an AI-Generated Summary
Comments (0)